Study: Peanut Allergy Drops Safe, Effective for Toddlers By Fran Lowry
March 1, 2021 Allergy drops administered under the tongue are safe and effective as treatment for peanut allergy, even in children as young as 1, according to new research.
In a double-blind, placebo-controlled trial of 36 children ages 1 to 4 years old who were allergic to peanuts, those who were randomly assigned to receive peanut immunotherapy drops showed significant desensitization to peanuts at the end of the 3-year trial compared with children who received placebo.
In addition, there was a strong potential that the treatment lasted 3 months after the trial ended for the toddlers who received the active treatment, according to the researchers.
Novel Agent Shows Promise Against Cat Allergy
medscape.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medscape.com Daily Mail and Mail on Sunday newspapers.
Peanut Sublingual Immunotherapy Feasible and Effective in Toddlers
medscape.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medscape.com Daily Mail and Mail on Sunday newspapers.
Ukko Secures $40 Million in Series B Funding Led by Leaps by Bayer to Overcome Food Allergies and Sensitivities
Top industry leaders and venture firms unite behind Ukko s efforts to eliminate the world s most prevalent food allergies and sensitivities, including peanuts and gluten
News provided by
Share this article
Share this article
PALO ALTO, Calif., TEL AVIV, Israel and LEVERKUSEN, Germany, Jan. 27, 2021 /PRNewswire/ Ukko, a biotech company with the mission to eliminate food allergies and sensitivities, today announced $40 million in new Series B funding. Ukko harnesses artificial intelligence (AI) and protein engineering to develop healthier food and therapies for food allergies. The new funding will allow Ukko to enter clinical trials with its investigational therapeutic for peanut allergy. It will also accelerate development of Ukko s gluten that is designed for people with celiac and other gluten sensitivities. The round was led by Leaps by Bayer – the impact investm